Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Ultrasensitive Luminescence-based Yeast Sensors for Specific Early Cancer Sensing

Project description

Using worm biology to detect cancer

Early detection remains a major challenge for breast and prostate cancer. Current screening tools are invasive or prohibitively expensive, limiting patients’ ability to get a timely diagnosis. Researchers are now turning to a small worm as a potential solution. This worm has a highly sensitive sense of smell that can detect chemical signals associated with cancer. The EIC-funded ULYSSES project aims to develop a portable urine test to identify cancer markers. It will use yeast cells containing olfactory receptors from the worm that connect to a light-emitting sensing system. When molecules associated with cancer interact with these engineered yeast cells, they will trigger a measurable optical signal. The device will use machine learning to interpret these signals, rapidly detecting cancer signatures non-invasively.

Objective

ULYSSES is a pioneering project aimed at developing a non-invasive, portable, and user-friendly biosensor for the early detection of breast and prostate cancers through urine analysis. Its core vision is to identify cancer-related volatile organic compounds (VOCs) and develop a biotechnological device for their detection in urine. The innovation lies in mimicking the extraordinary olfactory system of the nematode Caenorhabditis elegans, which can distinguish cancerous from healthy urine with over 90% accuracy. This ability is mediated by a large repertoire of olfactory receptors (ORs) expressed on specialized sensory neurons. ULYSSES replicates this sensing capacity in a synthetic biology framework by introducing selected C. elegans ORs into engineered yeast (Saccharomyces cerevisiae). These ORs are functionally coupled to a bioluminescence resonance energy transfer (BRET)-based biosensing construct. Upon binding cancer-associated VOCs, conformational changes in the ORs trigger measurable BRET signal shifts, serving as indicators of cancer-specific profiles with nanomolar sensitivity. In parallel, urine VOCs will be analysed via gas chromatography–mass spectrometry (GC-MS). Machine learning will be applied to the spectral data to identify key compounds that differentiate cancer from healthy samples and link them to specific OR activation profiles. Engineered yeast biosensors, each with a distinct OR-BRET construct, will be arrayed on a disposable device. Upon urine exposure, BRET signal changes will be recorded and interpreted via an AI algorithm trained on activation heatmaps. This enables the identification of cancer-related patterns with high sensitivity and specificity. Feasibility is ensured by the convergence of expertise within a strongly interdisciplinary consortium. ULYSSES lays the foundation for a versatile diagnostic platform with broad applications in health monitoring and personalized medicine, with strong potential for societal and healthcare impact.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-EIC - HORIZON EIC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIC-2025-PATHFINDEROPEN

See all projects funded under this call

Coordinator

DISRUPTIVE TECHNOLOGICAL ADVANCES IN LIFE SCIENCE S.R.L. - SOCIETA BENEFIT, IN FORMA ABBREVIATA D-TAILS S.R.L. SB
Net EU contribution
€ 1 100 000,00
Address
Via Agrigento 4A-4B
00161 Roma
Italy
SME
Yes
Region
Centro (IT) Lazio Roma
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 1 100 000,00

Participants (3)